Skip to main content
Back
Watch Compare

Can-Fite BioPharma Ltd.

Data quality: 100%
CANF
NYSE Manufacturing Chemicals
$2.99
▼ $0.09 (-2.82%)
Mkt Cap: 7.02 M
Price
$2.99
Mkt Cap
7.02 M
Day Range
$2.94 — $3.16
52-Week Range
$2.94 — $36.40
Volume
54,522
Open $3.07
50D / 200D Avg
$4.05
26.02% below
50D / 200D Avg
$9.54
68.62% below

Quick Summary

Key Takeaways

Revenue declined -16.99% annually over 5 years
Negative free cash flow of -8.95 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 22.92%
Capital efficient — spends only 0.49% of revenue on capex

Growth

Revenue Growth (5Y)
-16.99%
Below sector avg (1.82%)
Revenue (1Y)-39.91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-295.00%
Below sector avg (-53.47%)
ROIC-164.88%
Net Margin-2426.67%
Op. Margin-2456.79%

Safety

Debt / Equity
N/A
Current Ratio3.60
Interest Coverage-35.04

Valuation

PE (TTM)
-0.71
Above sector avg (-1.47)
P/B Ratio1.68
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.7 -1.5
P/B 1.7 1.6
ROE % -295.0 -53.5
Net Margin % -2426.7 -41.5
Rev Growth 5Y % -17.0 1.8
D/E — 0.3

ETFs Holding This Stock

AVEE logo AVEE Avantis Emerging Markets Small Cap Equity ETF
0.05% weight
AVES logo AVES Avantis Emerging Markets Value ETF
0.04% weight
IND logo IND Xtrackers Nifty 500 India ETF
0.04% weight
AVSE logo AVSE Avantis Responsible Emerging Markets Equity ETF
0.03% weight
AVXC logo AVXC Avantis Emerging Markets ex-China Equity ETF
0.02% weight
WLCTX WLCTX
0.01% weight
WLTTX WLTTX
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -39.91% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -16.99% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 405,000.0 Net Income (TTM) -9.83 M
ROE -295.00% ROA -144.08%
Gross Margin N/A Operating Margin -2456.79%
Net Margin -2426.67% Free Cash Flow (TTM) -8.95 M
ROIC -164.88% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.60
Interest Coverage -35.04 Asset Turnover 0.06
Working Capital 5.50 M Tangible Book Value 4.18 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.71 Forward P/E N/A
P/B Ratio 1.68 P/S Ratio 17.34
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -127.44%
Market Cap 7.02 M Enterprise Value 569,538.0
Per Share
EPS (Diluted TTM) -5.97 Revenue / Share 0.17
FCF / Share -3.81 OCF / Share -3.81
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.49% FCF Conversion 91.08%
SBC-Adj. FCF -9.63 M Growth Momentum -22.92

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 405,000.0 674,000.0 — 810,000.0 853,000.0
Net Income -9.83 M -7.88 M -7.63 M -10.17 M -12.62 M
EPS (Diluted) -5.97 0.00 -0.01 -0.01 —
Gross Profit — — — — —
Operating Income -9.95 M -8.13 M -8.20 M -10.10 M -12.84 M
EBITDA — — — — —
R&D Expenses 6.69 M 5.76 M 5.98 M 7.76 M 9.85 M
SG&A Expenses — — — 263,000.0 —
D&A 24,000.0 — — 14,000.0 14,000.0
Interest Expense 284,000.0 -291,000.0 — -77,000.0 227,000.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.51 M 9.12 M 9.99 M 9.28 M 20.25 M
Total Liabilities — — — — —
Shareholders' Equity 5.59 M 5.44 M 6.24 M 4.47 M 14.38 M
Total Debt — — — — —
Cash & Equivalents 5.53 M 4.83 M 4.28 M 2.98 M 4.39 M
Current Assets 9.44 M 8.98 M 9.91 M 9.16 M 20.07 M
Current Liabilities 2.73 M 2.05 M 2.02 M 2.50 M 2.73 M